Allogeneic marrow transplantation for the treatment of leukaemia. A review.
22 HL-A antigen and mixed leukocyte culture-matched sibling bone marrow transplants were attempted in patients with acute leukaemia (at the National Cancer Institute) to define the toxicities of four different immunosuppressive regimens, the complications associated with warrow engraftment and antileukaemic effect. 73% (16/22) were engrafted as indicated by a change to donor red blood cells (RBC) type, leukocyte, immunoglobulin allotype or by the speed of morrow repopulation and the occurrence of the Graft Versus Host Disease (GVHD). 12 of 16 (75%) successful engrafted patients developed  GVHD. The current published results of clinical bone marrow transplantation from major centers has been reviewed and will be discussed in relationship to current clinical complications associated with bone marrow transplantation.
D000293:Adolescent; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D005069:Evaluation Studies as Topic; D005260:Female; D006087:Graft vs Host Reaction; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007136:Immunoglobulins; D007165:Immunosuppression Therapy; D007938:Leukemia / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000276:immunology / Q000628:therapy; D007948:Leukemia, Monocytic, Acute / Q000276:immunology / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D014184:Transplantation, Homologous
D006680:HLA Antigens; D007136:Immunoglobulins